Multicenter Phase II Study of Gefitinib Mono-therapy or Gefitinib Combined With Pemetrexed/Cisplatin in Patients With Brain Metastases From Non-small Cell Lung Cancer Harboring EGFR Mutation
Phase of Trial: Phase II
Latest Information Update: 01 Apr 2015
At a glance
- Drugs Gefitinib (Primary) ; Cisplatin; Pemetrexed
- Indications Brain metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 29 Mar 2015 Planned End Date changed from 1 Jun 2015 to 1 Jun 2017 as reported by ClinicalTrials.gov record.
- 29 Mar 2015 Planned primary completion date changed to 1 Jun 2016 as reported by ClinicalTrials.gov record.